On ECHEMI
Home > Drugs > Duloxetine hydrochloride Registered Holders
Duloxetine hydrochloride structure

Duloxetine hydrochloride structure

Duloxetine hydrochloride

In addition, duloxetine recipients experienced significantly greater increases in their average voiding interval than placebo recipients (15.0–20.4 versus 1.7–8.5 minutes). The most commonly observed adverse events associated with duloxetine therapy are nausea, dry mouth, constipation, decreased appetite, fatigue, somnolence, and increased sweating. As with other 5-HT reuptake inhibitors, duloxetine is contraindicated in patients taking MAO inhibitors. Additionally, it is contraindicated

Find 88 Related Holders

HEC PHARM CO LTD
United States United States

API Registration Country

API Active
MSN LABORATORIES PRIVATE LTD
United States United States

API Registration Country

API Active
RL FINE CHEM PVT LTD
United States United States

API Registration Country

API Active
ORBION PHARMACEUTICALS PRIVATE LTD
United States United States

API Registration Country

API Active
MATRIX PHARMACORP PRIVATE LTD
United States United States

API Registration Country

API Active
ALEMBIC PHARMACEUTICALS LTD
United States United States

API Registration Country

API Active
APITORIA PHARMA PRIVATE LTD
United States United States

API Registration Country

API Active
JUBILANT PHARMOVA LTD
United States United States

API Registration Country

API Active
SIGNA SA DE CV
United States United States

API Registration Country

API Active
TORRENT PHARMACEUTICALS LTD
India India

API Registration Country

API Active
  • Founded in:

    1972-07-15 00:00:00
  • Country:

    India India
  • Address:

    TORRENT HOUSEOFF ASHRAM ROAD NAVARANGPURA 9 NA AHMEDABAD GJ IN
  • Registered Funds:

    1.7 billion INR
Recommended Suppliers of Duloxetine hydrochloride
View 94 Suppliers Request for Quotation
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.